Cadila Healthcare’s Moraiya facility successfully completes USFDA inspection
11 September 2017 | News
The company has also received the final approval from the USFDA to market Mycophenolate Mofetil for Injection USP, 500 mg/vial
Source: Pixabay
Cadila Healthcare Limited has recently announced that the USFDA inspected its Moraiya facility from 31st August 2017 to 7th September, 2017. At the end of the inspection, no observation (483) is issued.
The company has also received the final approval from the USFDA to market Mycophenolate Mofetil for Injection USP, 500 mg/vial. This drug is indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants. The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
